E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancer |
|
E.1.1.1 | Medical condition in easily understood language |
blood clot in leg veins and/or in the pulmonary artery in the lungs |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through 6 months post randomization in patients with GI or GU cancer and recently diagnosed VTE. If non-inferiority is demonstrated, then superiority will be assessed. |
|
E.2.2 | Secondary objectives of the trial |
1. To assess whether abelacimab is superior to dalteparin for preventing occurrence of the composite of major or CRNM bleeding 2. To assess whether abelacimab is superior to dalteparin on net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding events 3. To assess whether abelacimab is superior to dalteparin on the rate of permanent treatment discontinuation not due to death 4. To assess whether abelacimab is superior to dalteparin for preventing occurrence of CRNM bleeding events 5. To assess whether abelacimab is superior to dalteparin for preventing occurrence of major bleeding events 6. To assess whether abelacimab is superior to dalteparin for preventing occurrence of the composite of GI major and CRNM bleeding 7. To evaluate safety and tolerability of abelacimab relative to dalteparin and to assess the incidence rate of injection site reactions, hypersensitivity reactions and immunogenicity in patients treated with abelacimab
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomic study requiring samples to be collected at Day 1 (DNA). |
|
E.3 | Principal inclusion criteria |
• Male or female subjects ≥18 years old or other legal maturity age according to the country of residence • Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if: o Unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer and o No intended curative surgery during the study • Confirmed symptomatic or incidental proximal lower limb acute DVT (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic PE, or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 72 hours from diagnosis of the qualifying VTE. • Anticoagulation therapy with LMWH for at least 6 months is indicated. • Able to provide written informed consent
|
|
E.4 | Principal exclusion criteria |
• Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE • More than 72 hours of pre-treatment with therapeutic doses of UFH, LMWH, or other anticoagulants • An indication to continue treatment with therapeutic doses of an anticoagulant other than that for VTE treatment prior to randomization (e.g., AF, mechanical heart valve, prior VTE) • PE leading to hemodynamic instability (blood pressure [BP] <90 mmHg or shock) • Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within 4 weeks of screening • Brain trauma or a cerebral or spinal cord surgery within 4 weeks of screening • Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin • Bleeding requiring medical attention at the time of randomization or within the preceding 4 weeks • Planned major surgery at baseline • History of heparin-induced thrombocytopenia • Infective acute or subacute endocarditis at the time of presentation • Primary brain cancer or untreated intracranial metastasis • Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening • Life expectancy <3 months at randomization • Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) • Platelet count <50,000/mm3 • Hemoglobin <8 g/dL • Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase (ALT) ≥3 x and/or bilirubin ≥2 x upper limit of normal (ULN) in absence of clinical explanation • Uncontrolled hypertension (systolic BP >180 mm Hg or diastolic BP >100 mm Hg) despite antihypertensive treatment • Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab (See Section 5.3.6 for highly effective contraceptive measures) • Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab. • Pregnant or breast-feeding women • History of hypersensitivity to any of the study drugs (including dalteparin) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for dalteparin • Subjects with any condition that in the Investigator’s judgement would place the subject at increased risk of harm if he/she participated in the study • Use of other investigational (not-registered) drugs within 5 half-lives prior to enrollment or until the expected PD effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies testing different strategies or different combinations of registered drugs is permitted. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first event of centrally adjudicated VTE recurrence |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 months post randomization |
|
E.5.2 | Secondary end point(s) |
1. Time to first event of ISTH-adjudicated major or CRNM bleeding events 2. Time to first event of VTE recurrence, ISTH-adjudicated major or ISTH-adjudicated CRNM bleeding events 3. To assess whether abelacimab is superior to dalteparin on the rate of permanent treatment discontinuation not due to death 4. Time to first event of ISTH-adjudicated CRNM bleeding events 5. Time to first event of ISTH-adjudicated major bleeding events 6. Time to first event of GI ISTH-adjudicated major and GI CRNM bleeding events 7. All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years • For patients treated with abelacimab: o Percentage of patients with injection site reactions o Percentage of patients with injection site reactions by severity status o Percentage of patients with hypersensitivity reactions o Percentage of patients with hypersensitivity reactions by severity status o Percentage of patients with ADA formation o Percentage of patients with persistent ADA formation o Percentage of patients with neutralizing antibody (NAb) formation.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
6 months post randomization |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 160 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
China |
Japan |
Korea, Republic of |
Taiwan |
United States |
France |
Latvia |
Sweden |
Netherlands |
Spain |
Switzerland |
Czechia |
Germany |
Italy |
Hungary |
Ireland |
Norway |
Ukraine |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |